Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$6,731,142

1,767 payments

Through program year 2025, Valley Clinical Trials is reported as receiving $6,731,142 in research payments, across 1,767 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,608,306 245
2024 Research $1,358,662 95
2023 Research $845,638 370
2022 Research $869,955 144
2021 Research $952,580 217
2020 Research $1,066,766 599
2019 Research $29,236 97

Breakdown

Who paid Research payments · program years 2019–2025
  1. American Regent $1,437,553 97 payments
  2. Novartis Pharmaceuticals Corporation $1,385,820 36 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,381,525 56 payments
  4. AstraZeneca UK Limited $1,110,383 12 payments
  5. Novo Nordisk AS $751,341 1,145 payments
  6. Boehringer Ingelheim International GmbH $219,337 244 payments
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $131,566 15 payments
  8. Impulse Dynamics (USA) Inc. $116,925 73 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $46,013 16 payments
  10. AstraZeneca Pharmaceuticals LP $42,597 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Heart_FID $1,142,425 75 payments
  2. Ex9536-4388 $586,930 769 payments
  3. A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure $541,597 1 payment
  4. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $505,962 8 payments
  5. Phase II study of BI456906 patients with T2DM Obes $456,232 4 payments
  6. Obesity Long term safety in patients with CV risk $451,684 6 payments
  7. Heart_FID $295,128 22 payments
  8. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $286,600 5 payments
  9. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $268,015 144 payments
  10. A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N terminal Prohormone Brain Natriuretic Peptide $242,772 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record